Transcriptomic analysis reveals inhibition of androgen receptor activity by AMPK in prostate cancer cells

por Jurmeister, Sarah, Ramos-Montoya, Antonio, Neal, David E., Fryer, Lee G D
Publicado 2014

Stat3 controls cell death during mammary gland involution by regulating uptake of milk fat globules and lysosomal membrane permeabilization

por Sargeant, Timothy J., Lloyd-Lewis, Bethan, Resemann, Henrike K., Ramos-Montoya, Antonio, Skepper, Jeremy, Watson, Christine J.
Publicado 2014

Optimizing the design of population-based patient-derived tumor xenograft studies to better predict clinical response

por Floc'h, Nicolas, Guerriero, Maria Luisa, Ramos-Montoya, Antonio, Davies, Barry R., Cairns, Jonathan, Karp, Natasha A.
Publicado 2018

Loss of hSef promotes metastasis through upregulation of EMT in prostate cancer

por Hori, Satoshi, Wadhwa, Karan, Pisupati, Venkat, Zecchini, Vincent, Ramos‐Montoya, Antonio, Warren, Anne Y, Neal, David E, Gnanapragasam, Vincent J
Publicado 2017

Asporin is a stromally expressed marker associated with prostate cancer progression

por Rochette, Annie, Boufaied, Nadia, Scarlata, Eleonora, Hamel, Lucie, Brimo, Fadi, Whitaker, Hayley C, Ramos-Montoya, Antonio, Neal, David E, Dragomir, Alice, Aprikian, Armen, Chevalier, Simone, Thomson, Axel A
Publicado 2017

Identification of potential therapeutic targets in prostate cancer through a cross‐species approach

por Jurmeister, Sarah, Ramos‐Montoya, Antonio, Sandi, Chiranjeevi, Pértega‐Gomes, Nelma, Wadhwa, Karan, Lamb, Alastair D, Dunning, Mark J, Attig, Jan, Carroll, Jason S, Fryer, Lee GD, Felisbino, Sérgio L, Neal, David E
Publicado 2018

Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells

por Lloyd, Rebecca L., Wijnhoven, Paul W. G., Ramos-Montoya, Antonio, Wilson, Zena, Illuzzi, Giuditta, Falenta, Katarzyna, Jones, Gemma N., James, Neil, Chabbert, Christophe D., Stott, Jonathan, Dean, Emma, Lau, Alan, Young, Lucy A.
Publicado 2020

The ETS family member GABPα modulates androgen receptor signalling and mediates an aggressive phenotype in prostate cancer

por Sharma, Naomi L., Massie, Charlie E., Butter, Falk, Mann, Matthias, Bon, Helene, Ramos-Montoya, Antonio, Menon, Suraj, Stark, Rory, Lamb, Alastair D., Scott, Helen E., Warren, Anne Y., Neal, David E., Mills, Ian G.
Publicado 2014

Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control

por Nakamura, Kyoko, Karmokar, Ankur, Farrington, Paul M., James, Neil H., Ramos-Montoya, Antonio, Bickerton, Susan J., Hughes, Gareth D., Illidge, Timothy M., Cadogan, Elaine B., Davies, Barry R., Dovedi, Simon J., Valge-Archer, Viia
Publicado 2021

HES5 silencing is an early and recurrent change in prostate tumourigenesis

por Massie, Charles E, Spiteri, Inmaculada, Ross-Adams, Helen, Luxton, Hayley, Kay, Jonathan, Whitaker, Hayley C, Dunning, Mark J, Lamb, Alastair D, Ramos-Montoya, Antonio, Brewer, Daniel S, Cooper, Colin S, Eeles, Rosalind, Warren, Anne Y, Tavaré, Simon, Neal, David E, Lynch, Andy G
Publicado 2015

A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy

por Pertega‐Gomes, Nelma, Felisbino, Sergio, Massie, Charlie E, Vizcaino, Jose R, Coelho, Ricardo, Sandi, Chiranjeevi, Simoes‐Sousa, Susana, Jurmeister, Sarah, Ramos‐Montoya, Antonio, Asim, Mohammad, Tran, Maxine, Oliveira, Elsa, Lobo da Cunha, Alexandre, Maximo, Valdemar, Baltazar, Fatima, Neal, David E, Fryer, Lee GD
Publicado 2015

Independence of HIF1a and androgen signaling pathways in prostate cancer

por Tran, Maxine G. B., Bibby, Becky A. S., Yang, Lingjian, Lo, Franklin, Warren, Anne Y., Shukla, Deepa, Osborne, Michelle, Hadfield, James, Carroll, Thomas, Stark, Rory, Scott, Helen, Ramos-Montoya, Antonio, Massie, Charlie, Maxwell, Patrick, West, Catharine M. L., Mills, Ian G., Neal, David E.
Publicado 2020

VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status

por Bizzaro, Francesca, Fuso Nerini, Ilaria, Taylor, Molly A., Anastasia, Alessia, Russo, Massimo, Damia, Giovanna, Guffanti, Federica, Guana, Francesca, Ostano, Paola, Minoli, Lucia, Hattersley, Maureen M., Arnold, Stephanie, Ramos-Montoya, Antonio, Williamson, Stuart C., Galbiati, Alessandro, Urosevic, Jelena, Leo, Elisabetta, Cavallaro, Ugo, Ghilardi, Carmen, Barry, Simon T., Bani, Maria Rosa, Giavazzi, Raffaella
Publicado 2021

pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry

por Jones, Gemma N., Rooney, Claire, Griffin, Nicola, Roudier, Martine, Young, Lucy A., Garcia-Trinidad, Antonio, Hughes, Gareth D., Whiteaker, Jeffrey R., Wilson, Zena, Odedra, Rajesh, Zhao, Lei, Ivey, Richard G., Howat, William J., Harrington, Elizabeth A., Barrett, J. Carl, Ramos-Montoya, Antonio, Lau, Alan, Paulovich, Amanda G., Cadogan, Elaine B., Pierce, Andrew J.
Publicado 2018

HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network

por Ramos-Montoya, Antonio, Lamb, Alastair D, Russell, Roslin, Carroll, Thomas, Jurmeister, Sarah, Galeano-Dalmau, Nuria, Massie, Charlie E, Boren, Joan, Bon, Helene, Theodorou, Vasiliki, Vias, Maria, Shaw, Greg L, Sharma, Naomi L, Ross-Adams, Helen, Scott, Helen E, Vowler, Sarah L, Howat, William J, Warren, Anne Y, Wooster, Richard F, Mills, Ian G, Neal, David E
Publicado 2014

The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer

por Shaw, Greg L., Whitaker, Hayley, Corcoran, Marie, Dunning, Mark J., Luxton, Hayley, Kay, Jonathan, Massie, Charlie E., Miller, Jodi L., Lamb, Alastair D., Ross-Adams, Helen, Russell, Roslin, Nelson, Adam W., Eldridge, Matthew D., Lynch, Andrew G., Ramos-Montoya, Antonio, Mills, Ian G., Taylor, Angela E., Arlt, Wiebke, Shah, Nimish, Warren, Anne Y., Neal, David E.
Publicado 2016

HNF1B variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer

por Ross-Adams, Helen, Ball, Stephen, Lawrenson, Kate, Halim, Silvia, Russell, Roslin, Wells, Claire, Strand, Siri H., Ørntoft, Torben F., Larson, Melissa, Armasu, Sebastian, Massie, Charles E., Asim, Mohammad, Mortensen, Martin M., Borre, Michael, Woodfine, Kathryn, Warren, Anne Y., Lamb, Alastair D., Kay, Jonathan, Whitaker, Hayley, Ramos-Montoya, Antonio, Murrell, Adele, Sørensen, Karina D., Fridley, Brooke L., Goode, Ellen L., Gayther, Simon A., Masters, John, Neal, David E., Mills, Ian G.
Publicado 2016

AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity

por Fok, Jacqueline H. L., Ramos-Montoya, Antonio, Vazquez-Chantada, Mercedes, Wijnhoven, Paul W. G., Follia, Valeria, James, Neil, Farrington, Paul M., Karmokar, Ankur, Willis, Sophie E., Cairns, Jonathan, Nikkilä, Jenni, Beattie, David, Lamont, Gillian M., Finlay, M. Raymond V., Wilson, Joanne, Smith, Aaron, O’Connor, Lenka Oplustil, Ling, Stephanie, Fawell, Stephen E., O’Connor, Mark J., Hollingsworth, Simon J., Dean, Emma, Goldberg, Frederick W., Davies, Barry R., Cadogan, Elaine B.
Publicado 2019